Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Xueshuantong Capsule for prevention of heart failure after PCI in acute myocardial infarction
ChiCTR1900026545Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Oct 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in myocardial infarction (MI) comparing Conventional medicine + placebo with Conventional medicine + Compound Xueshuantong Capsule (2 arms). Primary endpoint: Incidence of heart failure at month 3. Started Oct 2019; status: recruiting.
02
Drugs
Fufang Xueshuantong
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR1900026545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026545.